

Compounding Pharmacies Market By Therapeutic Area (Pain Management, Hormone Replacement Therapy, Dermal Disorders, Nutritional Supplements, Others), By Route of Administration (Oral, Topical, Others), By Sterility (Non-Sterile Compounding Drugs, Sterile Compounding Drugs): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-07-01 | 268 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$3110.40
- Business User License \$5238.00
- Enterprise License \$8640.00

Report description:

Compounding is preparation of a custom formulation of a medication to fit a unique need of a patient that cannot be met with commercially available products. They are able to make unique medications for each person as some people need drugs that are not available on the market. Compounding pharmacies can be of assistance in this situation since there are several potential causes for this need. Compounding pharmacies can create sterile and non-sterile chemicals. While some pharmacies may provide services for both types of compounding, others may only specialize in one. Injections, ocular drops, and infusions are examples of dosage forms that contain sterile substances.

The major factors that drive the growth of the global compound pharmacies market include increase in prevalence of chronic disease, high adoption of non-sterile medication, increase in old age population and improved life expectancy. In addition, growing drug failure rate, increase in popularity of personalized medicine and massive drug shortage across the globe is further propel the market growth during forecast period. However, increase in restrictions on manufacturing of complex formulation is likely to restrain the growth of the compounding pharmacies market during the forecast period. Conversely, growth potential of emerging economies is anticipated to provide numerous opportunities for market growth during the forecast period.

The compounding pharmacies market is segmented into therapeutic area, route of administration, sterility, and region. According to therapeutic area, the market is categorized into pain management, hormone replacement, dermal disorder, nutritional supplement and others. On the basis of route of administration, it is segmented into oral, topical and others. By end user, it is segregated into sterile compounding drugs and non-sterile compounding drugs. □Region wise, it is analyzed across North America,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include the Advance Pharmacy, Athenex pharma, B. Braun Melsungen AG, Dougherty's Pharmacy, Inc., Fresenius SE and Co. KGaA, Institutional pharmacy solutions, ITC compounding pharmacy, The McGuff Companies, Inc., Nephron pharmaceuticals, New Compounding Pharma, Olympia Pharmaceuticals, Panacea biomatx, Pencol compounding pharmacy, Perrigo Company plc, Rx express compounding pharmacy, RX3 compounding pharmacy, Valor Compounding Pharmacy.

Key Benefits For Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding pharmacies market analysis from 2021 to 2031 to identify the prevailing compounding pharmacies market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the compounding pharmacies market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global compounding pharmacies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapeutic Area

- Pain Management
- Hormone Replacement Therapy
- Dermal Disorders
- Nutritional Supplements
- Others

By Route of Administration

- Oral
- Topical
- Others

By Sterility

- Non-Sterile Compounding Drugs
- Distribution Channel
- Hospital Pharmacy
- Compounding Pharmacy
- Others
- Sterile Compounding Drugs
- Distribution Channel
- Hospital Pharmacy
- Compounding Pharmacy
- Others

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Italy
- Spain
- Rest of Europe
- Germany
- France
- UK
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Advanced Pharmacy
- Athenex Pharma Solutions
- B. Braun Melsungen AG
- Dougherty's Pharmacy, Inc.
- Fresenius SE and Co. KGaA
- Institutional pharmacy solutions
- ITC compounding pharmacy
- McGuff Companies, Inc.
- Nephron pharmaceuticals
- New Compounding Pharma
- Olympia Compounding Pharmacy
- Panacea Biomatx Inc (Triangle Compounding Pharmacy)
- Pencol compounding pharmacy
- Perrigo Company Plc (Fagron)
- Rx express compounding pharmacy
- RX3 compounding pharmacy
- Valor Compounding Pharmacy

Table of Contents:

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.Key findings of the study

2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter's five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA

4.1 Overview

4.1.1 Market size and forecast

4.2 Pain Management

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Hormone Replacement Therapy

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Dermal Disorders

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Nutritional Supplements

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

4.6 Others

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market analysis by country

CHAPTER 5: COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION

5.1 Overview

5.1.1 Market size and forecast

5.2 Oral

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Topical

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

CHAPTER 6: COMPOUNDING PHARMACIES MARKET, BY STERILITY

6.1 Overview

6.1.1 Market size and forecast

6.2 Non-Sterile Compounding Drugs

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Non-Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel

6.3 Sterile Compounding Drugs

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.3.4 Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel

CHAPTER 7: COMPOUNDING PHARMACIES MARKET, BY REGION

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Therapeutic Area

7.2.3 North America Market size and forecast, by Route of Administration

7.2.4 North America Market size and forecast, by Sterility

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Therapeutic Area

7.2.5.1.2 Market size and forecast, by Route of Administration

7.2.5.1.3 Market size and forecast, by Sterility

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Therapeutic Area

7.2.5.2.2 Market size and forecast, by Route of Administration

7.2.5.2.3 Market size and forecast, by Sterility

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Therapeutic Area

7.2.5.3.2 Market size and forecast, by Route of Administration

7.2.5.3.3 Market size and forecast, by Sterility

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Therapeutic Area

7.3.3 Europe Market size and forecast, by Route of Administration

7.3.4 Europe Market size and forecast, by Sterility

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Therapeutic Area

7.3.5.1.2 Market size and forecast, by Route of Administration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.5.1.3 Market size and forecast, by Sterility
- 7.3.5.2 France
 - 7.3.5.2.1 Market size and forecast, by Therapeutic Area
 - 7.3.5.2.2 Market size and forecast, by Route of Administration
 - 7.3.5.2.3 Market size and forecast, by Sterility
- 7.3.5.3 UK
 - 7.3.5.3.1 Market size and forecast, by Therapeutic Area
 - 7.3.5.3.2 Market size and forecast, by Route of Administration
 - 7.3.5.3.3 Market size and forecast, by Sterility
- 7.3.5.4 Italy
 - 7.3.5.4.1 Market size and forecast, by Therapeutic Area
 - 7.3.5.4.2 Market size and forecast, by Route of Administration
 - 7.3.5.4.3 Market size and forecast, by Sterility
- 7.3.5.5 Spain
 - 7.3.5.5.1 Market size and forecast, by Therapeutic Area
 - 7.3.5.5.2 Market size and forecast, by Route of Administration
 - 7.3.5.5.3 Market size and forecast, by Sterility
- 7.3.5.6 Rest of Europe
 - 7.3.5.6.1 Market size and forecast, by Therapeutic Area
 - 7.3.5.6.2 Market size and forecast, by Route of Administration
 - 7.3.5.6.3 Market size and forecast, by Sterility
- 7.4 Asia-Pacific
 - 7.4.1 Key trends and opportunities
 - 7.4.2 Asia-Pacific Market size and forecast, by Therapeutic Area
 - 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
 - 7.4.4 Asia-Pacific Market size and forecast, by Sterility
 - 7.4.5 Asia-Pacific Market size and forecast, by country
 - 7.4.5.1 Japan
 - 7.4.5.1.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.1.2 Market size and forecast, by Route of Administration
 - 7.4.5.1.3 Market size and forecast, by Sterility
 - 7.4.5.2 China
 - 7.4.5.2.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.2.2 Market size and forecast, by Route of Administration
 - 7.4.5.2.3 Market size and forecast, by Sterility
 - 7.4.5.3 India
 - 7.4.5.3.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.3.2 Market size and forecast, by Route of Administration
 - 7.4.5.3.3 Market size and forecast, by Sterility
 - 7.4.5.4 Australia
 - 7.4.5.4.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.4.2 Market size and forecast, by Route of Administration
 - 7.4.5.4.3 Market size and forecast, by Sterility
 - 7.4.5.5 South Korea
 - 7.4.5.5.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.5.2 Market size and forecast, by Route of Administration
 - 7.4.5.5.3 Market size and forecast, by Sterility

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5.6 Rest of Asia-Pacific
 - 7.4.5.6.1 Market size and forecast, by Therapeutic Area
 - 7.4.5.6.2 Market size and forecast, by Route of Administration
 - 7.4.5.6.3 Market size and forecast, by Sterility
- 7.5 LAMEA
 - 7.5.1 Key trends and opportunities
 - 7.5.2 LAMEA Market size and forecast, by Therapeutic Area
 - 7.5.3 LAMEA Market size and forecast, by Route of Administration
 - 7.5.4 LAMEA Market size and forecast, by Sterility
 - 7.5.5 LAMEA Market size and forecast, by country
 - 7.5.5.1 Brazil
 - 7.5.5.1.1 Market size and forecast, by Therapeutic Area
 - 7.5.5.1.2 Market size and forecast, by Route of Administration
 - 7.5.5.1.3 Market size and forecast, by Sterility
 - 7.5.5.2 Saudi Arabia
 - 7.5.5.2.1 Market size and forecast, by Therapeutic Area
 - 7.5.5.2.2 Market size and forecast, by Route of Administration
 - 7.5.5.2.3 Market size and forecast, by Sterility
 - 7.5.5.3 South Africa
 - 7.5.5.3.1 Market size and forecast, by Therapeutic Area
 - 7.5.5.3.2 Market size and forecast, by Route of Administration
 - 7.5.5.3.3 Market size and forecast, by Sterility
 - 7.5.5.4 Rest of LAMEA
 - 7.5.5.4.1 Market size and forecast, by Therapeutic Area
 - 7.5.5.4.2 Market size and forecast, by Route of Administration
 - 7.5.5.4.3 Market size and forecast, by Sterility

CHAPTER 8: COMPANY LANDSCAPE

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

- 9.1 Advanced Pharmacy
 - 9.1.1 Company overview
 - 9.1.2 Company snapshot
 - 9.1.3 Operating business segments
 - 9.1.4 Product portfolio
 - 9.1.5 Business performance
 - 9.1.6 Key strategic moves and developments
- 9.2 Athenex Pharma Solutions
 - 9.2.1 Company overview
 - 9.2.2 Company snapshot
 - 9.2.3 Operating business segments
 - 9.2.4 Product portfolio
 - 9.2.5 Business performance

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.6 Key strategic moves and developments
- 9.3 B. Braun Melsungen AG
 - 9.3.1 Company overview
 - 9.3.2 Company snapshot
 - 9.3.3 Operating business segments
 - 9.3.4 Product portfolio
 - 9.3.5 Business performance
 - 9.3.6 Key strategic moves and developments
- 9.4 Dougherty's Pharmacy, Inc.
 - 9.4.1 Company overview
 - 9.4.2 Company snapshot
 - 9.4.3 Operating business segments
 - 9.4.4 Product portfolio
 - 9.4.5 Business performance
 - 9.4.6 Key strategic moves and developments
- 9.5 Fresenius SE and Co. KGaA
 - 9.5.1 Company overview
 - 9.5.2 Company snapshot
 - 9.5.3 Operating business segments
 - 9.5.4 Product portfolio
 - 9.5.5 Business performance
 - 9.5.6 Key strategic moves and developments
- 9.6 Institutional pharmacy solutions
 - 9.6.1 Company overview
 - 9.6.2 Company snapshot
 - 9.6.3 Operating business segments
 - 9.6.4 Product portfolio
 - 9.6.5 Business performance
 - 9.6.6 Key strategic moves and developments
- 9.7 ITC compounding pharmacy
 - 9.7.1 Company overview
 - 9.7.2 Company snapshot
 - 9.7.3 Operating business segments
 - 9.7.4 Product portfolio
 - 9.7.5 Business performance
 - 9.7.6 Key strategic moves and developments
- 9.8 McGuff Companies, Inc.
 - 9.8.1 Company overview
 - 9.8.2 Company snapshot
 - 9.8.3 Operating business segments
 - 9.8.4 Product portfolio
 - 9.8.5 Business performance
 - 9.8.6 Key strategic moves and developments
- 9.9 Nephron pharmaceuticals
 - 9.9.1 Company overview
 - 9.9.2 Company snapshot
 - 9.9.3 Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 New Compounding Pharma
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Olympia Compounding Pharmacy
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Panacea Biomatx Inc (Triangle Compounding Pharmacy)
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Pencol compounding pharmacy
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Perrigo Company Plc (Fagron)
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Rx express compounding pharmacy
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 RX3 compounding pharmacy
- 9.16.1 Company overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Valor Compounding Pharmacy
 - 9.17.1 Company overview
 - 9.17.2 Company snapshot
 - 9.17.3 Operating business segments
 - 9.17.4 Product portfolio
 - 9.17.5 Business performance
 - 9.17.6 Key strategic moves and developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Compounding Pharmacies Market By Therapeutic Area (Pain Management, Hormone Replacement Therapy, Dermal Disorders, Nutritional Supplements, Others), By Route of Administration (Oral, Topical, Others), By Sterility (Non-Sterile Compounding Drugs, Sterile Compounding Drugs): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-07-01 | 268 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$3110.40
	Business User License	\$5238.00
	Enterprise License	\$8640.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>